A parallel group, single-blind, randomised, placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of GW823296 [orvepitant] and its effect on the pharmacokinetics of midazolam after once-daily repeated oral doses in healthy subjects.

Trial Profile

A parallel group, single-blind, randomised, placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of GW823296 [orvepitant] and its effect on the pharmacokinetics of midazolam after once-daily repeated oral doses in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Orvepitant
  • Indications Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
    • 22 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top